The story with Hims & Hers Health today is the gap between the selloff and the scoreboard. The stock slipped about 4% to US$30.55 after earnings, even though Q2 revenue landed at US$753m and adjusted earnings before interest, tax, depreciation and amortization reached US$60m. That tension between a red screen and a growing telehealth platform is what matters for you as an investor.

Heading into the print, Hims & Hers Health had rallied sharply over the past three months, then cooled over the last week and month. This quarter now tests how much confidence the market really has in the business model and the path to sustained profit.

Love the growth story at Hims & Hers Health but concerned about how much of that story is already priced in after a sharp run up into earnings? Screen for telehealth peers and other fast growers with sturdier financial cushions using the list of solid balance sheet and fundamentals stocks (48 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$753m vs. US$544.833m (up about 38%)
• Net Income / Loss (Q2 2026 vs. Q2 2025): loss of US$86m vs. profit of US$42.505m (swung to a loss, partly tied to nonrecurring costs)
• Basic EPS (Q2 2026 vs. Q2 2025): loss per share vs. earnings of US$0.189438 (moved from profit to loss on a per share basis)
• Adjusted EBITDA (Q2 2026 vs. Q2 2025): US$60m (8% margin) vs. no prior-year figure disclosed (profit on an adjusted basis despite GAAP loss)

Prefer clean charts over a dense wall of earnings figures and commentary? View Hims & Hers Health's full financial picture to clearly see how the business earns and spends cash in the company report for Hims & Hers Health..

Evaluating Hims & Hers’ Platform Upside Against Q2 Reality

The bullish story on Hims & Hers is that a vertically integrated, AI driven, global telehealth platform will lift lifetime value, retention and margins as it scales. Q2 offers partial proof on scale, but mixed evidence on the margin piece. Revenue rose strongly and subscribers are now close to 3 million, which supports the idea that broader offerings like GLP 1 weight loss, testosterone and international brands are attracting more patients.

There are early signs that AI is doing real work, not just marketing. In the Hers weight loss pilot, AI handled about 80% of messages and cut nonclinical support tasks by about half, while operations and support delivered 3 points of sequential leverage. That is a concrete milestone for the automation thesis. At the same time, adjusted gross margin slipped to 64% and free cash flow stayed under pressure, which means the platform is not yet translating scale into cleaner profitability.

Reveal where the surface looks calm but the multi year models start to disagree on Hims & Hers Health's path from loss making GAAP results to adjusted profitability, and see what the street is quietly baking in for the next few years through the analyst estimates for Hims & Hers Health.

Hims & Hers Bear Case Finds Fresh Support

Bears argue that Hims & Hers Health is leaning too hard on GLP 1 and international growth while core economics weaken. This quarter gives that view more weight. Revenue reached US$753m and subscribers are near 3 million, yet adjusted gross margin slipped to 64% and free cash flow stayed negative. That directly echoes worries about pricing and margin pressure as the mix shifts toward branded weight loss and newer markets.

The bearish playbook also flags rising legal and regulatory risk and its impact on profits. The company moved from a profit a year ago to a GAAP net loss of US$86m in Q2, with about US$81m tied to Eucalyptus, restructuring and FTC related costs. That is a clear milestone missed on the path to cleaner earnings. Management talks about AI driven efficiency and long term EBITDA, but this print highlights how much execution and regulatory work still sits in front of Hims & Hers.

After such a sharp move from profit to a GAAP loss and fresh regulatory costs, it is fair to ask if this is a one off reset or the start of a tougher phase for Hims & Hers Health. Review the structured risk analysis for Hims & Hers Health which shows 1 important warning sign

Stay Ahead With Confident Decisions

If the mix of strong Q2 revenue for Hims & Hers Health and fresh regulatory costs has you watching for a better risk reward setup, register for free with Simply Wall St and add the stock to your Watchlist to track share price against fair value and earnings progress. Once you own any position, manage it through the Portfolio Command Center so you only see focused updates that matter for your thesis instead of day to day noise. For a longer term view, tap into the Community to see how other investors are thinking about catalysts like AI, GLP 1 exposure and free cash flow trends. That way you can spot hidden drivers and emerging risks early and stay a step ahead of the market.

Seeking Fresh Alternatives Beyond Hims & Hers

Some stocks may move before most investors who are still watching Hims & Hers Health. Scan fresh ideas with potential breakout characteristics before the crowd catches up and the edge diminishes.

• Identify potential momentum leaders early by scanning curated 71 profitable AI stocks that aren't just burning cash that already generate earnings instead of relying purely on hype or distant promises.
• Seek potential ballast for a choppy portfolio by reviewing a hand picked 83 resilient stocks with low risk scores that focuses on resilience when sentiment shifts and capital becomes more selective.
• Explore possible infrastructure-related opportunities by filtering a focused 37 power grid technology and infrastructure stocks that targets companies tied to grid upgrades, electrification and long term energy demand.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.